Alzheimer’s Disease Pipeline to Witness Large R&D Investment in the Coming Years

April 05 20:51 2017

According to a new research report “Alzheimer’s Disease Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Alzheimer’s disease currently exhibits a pipeline with 89 active drug candidates.

Alzheimer’s disease pipeline offers novel therapeutic targets for the treatment of Alzheimer’s disease

The study analyzed that the Alzheimer’s disease pipeline comprises 89 drug candidates, of which 17 products are in Phase III, 28 products are in Phase II, 28 products are in Phase I, 15 products are in Pre-Clinical stage and one product is in Discovery stage. Alzheimer’s disease is a common type of dementia and a fatal illness. It includes memory loss and loss of other intellectual abilities, which results in serious interference with the patient’s daily activities. Around 60% to 80% of dementia cases turn out to be Alzheimer’s disease and can cause problems with behavior, thinking and memory. Symptoms usually develop at a slower rate initially and becoming worse with time. Invasion of combination therapies, such as AVP-786, combination of deuterium modified dextromethorphan and ultra-low dose quinidine and use of various targets including amyloid- beta protein, tau protein is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis

Insights on pipeline segments

As per the findings of the research, around 48.0% active drug candidates of Alzheimer’s disease pipeline are being developed to be administered by oral route, 8.0% by intravenous route, 6.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by parenteral route and 6.0% are being developed to be administered by other routes which include intranasal, inhalation and intravenous or subcutaneous. Most of the drug candidates are being developed to be administered by oral route, due to high patient compliance. Route of administration of around 29.0% active drug candidates of Alzheimer’s disease pipeline are not disclosed.

Several companies are involved in the development of Alzheimer’s disease pipeline, with their products in different phases. Genentech, Inc., Eisai Co., Ltd. and AstraZeneca plc, each have their drug candidates in Phase III stage of development. Eli Lilly and Company is developing six products, out of which five are in Phase I and one is in Phase II stage.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis/report-sample

SupraAntigen technology platform for Alzheimer’s disease drug development

AC Immune, Ltd. is using SupraAntigen technology platform for the development of Crenezumab, ACI-24 and ACI-35 for Alzheimer’s disease. The SupraAntigen technology platform was initially developed by co-scientific founders, Dr. Claude Nicolau in collaboration with Dr. Fred van Leuven to solve the problem of the lack of immunogenicity of “self” proteins. This technology is used to produce conformation specific antibodies and is used to create products for active immunization (vaccines) and passive immunization (antibodies).

Major companies collaborate for the development of Alzheimer’s disease pipeline

The research finds that different companies have collaborated for the development of Alzheimer’s disease pipeline. In March 2014, Eisai Co., Ltd. and Biogen Idec collaborated to develop and commercialize two of Eisai’s clinical candidates, E2609 and BAN2401, for Alzheimer’s disease. Also, in April 2009, Bristol-Myers Squibb Company entered an agreement with Otsuka Pharmaceutical Co., Ltd. to extend the U.S. portion of the companies’ long-standing agreement for the development and commercialization of ABILIFY (aripiprazole).

Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., Bristol-Myers Squibb Company, Biogen Idec, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis Pharmaceuticals Corporation, AC Immune SA, Heptares Therapeutics and Probiodrug AG.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Web: https://www.psmarketresearch.com

Media Contact
Company Name: P&S Market Research
Contact Person: Abhishek
Email: Send Email
Phone: +1-888-778-7886
Address:347 5th Ave. #1402- 210
City: New York City
State: New York
Country: United States
Website: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis

  Categories: